Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 84

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 84
---
22,499 $19,916 $10,672 $20,040 Denominator:Weighted average shares outstanding, basic56,024,771 54,978,781 55,945,434 54,890,265 Effect of dilutive securities:Stock options and stock awards618,418 745,502 743,320 785,209 Weighted average shares outstanding, diluted56,643,189 55,724,283 56,688,754 55,675,474 Earnings per share, basic$0.40 $0.36 $0.19 $0.37 Earnings per share, diluted$0.40 $0.36 $0.19 $0.36 The following table sets forth the common stock equivalents of outstanding stock-based awards excluded in the calculation of diluted earnings per share, because their inclusion would be anti-dilutive:Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(unaudited)(unaudited)Stock options and stock awards588,422 971,683 836,462 799,798 

11.    Income Tax Expense (Benefit)

The following table provides information regarding the Company's income tax expense (benefit) for the three and six months ended June 30, 2025 and 2024 (dollars in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(unaudited)(unaudited)Income tax expense (benefit)$(5,830)$6,386 $166 $6,505 Effective tax rate(35.0)%24.3 %1.5 %24.5 %

17

Income tax benefit was $5.8 million ((35.0)% effective tax rate)) and income tax expense was $0.2 million (1.5% effective tax rate) for the three and six months ended June 30, 2025, as compared to an income tax expense of $6.4 million (24.3% effective tax rate) and $6.5 million (24.5% effective tax rate) for the three and six months ended June 30, 2024. The change in both periods was primarily due to decreased pre-tax book income for the three and six months ended June 30, 2025 as compared to the same